The 2015 American Society of Clinical Oncology (ASCO) meeting delivered news that payers and pathway developers will need to digest. Topics of discussion included:
- New breakthrough efficacy results from combined use of immuno-oncology/checkpoint inhibitors
- How payers and patients will cope